Cell cycle alterations are common in cancer and the G1/S checkpoint is frequently disrupted in breast cancer, leading to unchecked cellular proliferation.
INTRODUCTION
The G1/S checkpoint is frequently dysregulated in breast cancer (BC), leading to unchecked cellular proliferation. These include cyclin D1 overexpression or amplification, and loss of inhibitors p27 or p16 (1) (2) (3) . Such tumors demonstrate increased proliferative indices, as measured by elevated levels of KI-67 and increased phosphorylation of retinoblastoma (Rb) protein(4-7).
Palbociclib (PD0332991) is an oral inhibitor of the cyclin-dependent kinases (CDKs) 4 & 6(8) , preventing cell-cycle progression from G1 to S phase, thereby inhibiting cell proliferation and cellular DNA synthesis (9) . Activity, resulting in blockade of Rb phosphorylation and G1 arrest, was seen in Rb-positive tumor cell lines but not in Rb-negative MDA-MB-468 xenografts. In MDA-MB-435 xenografts, tumor growth suppression was shown to down-regulate E2F-regulated genes (CDC2, CCNE2, TK1, TOP2A). MMTV-c-neu mice treated with palbociclib showed marked reduction in tumor volume and improved median survival compared to untreated controls (10) , which was highly associated with presence of intact Rb and loss of p16..
In phase I, palbociclib was well tolerated and active, leading to a recommended phase II dose of 125 mg daily on a 3-week-on/1-week-off (3/1) schedule (11) .
Neutropenia was the dose-limiting toxicity; grade 3 neutropenia and anemia were seen in 12% and 7% of patients, respectively. The most common other toxicities were fatigue (34%), nausea (24%), constipation (17%), and vomiting (20%).
While there were no partial responses (PR) in phase I, stable disease (SD) was Author Manuscript Published OnlineFirst on December 11, 2014; DOI: 10.1158/1078-0432.CCR- seen in 35% of patients after 2 cycles, 27% of patients after 4 cycles and 16% of patients after 10 cycles. Notably, a heavily pretreated patient with ER+/Her2-BC achieved stable disease for 17 cycles.
Based on these findings, we conducted a phase II trial of palbociclib in patients with Rb-positive, advanced BC. Primary endpoints were disease response and tolerability; secondary endpoints included progression-free survival (PFS) and biomarker assessment to determine whether Rb localization, KI-67 index, p16 loss or CCND1 amplification were associated with response. Patients: Eligible patients had histologically confirmed metastatic BC staining positive for Rb (>1+ staining intensity as defined below) in primary or metastatic tumor, at least one measureable lesion by RECIST (V1.0)(13) and adequate organ and bone marrow function. There was no limit to the number of prior 
PATIENTS AND METHODS

Study
Treatment:
Palbociclib was administered at 125 mg orally once daily, on days 1-21 of a 28-day cycle, continuing until disease progression or unacceptable toxicity. Toxicity was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE V 3.0) in cycle 1 on days 1, 8, 15 and 21 and then on day 1 of subsequent cycles. In the event of grade 3/4 toxicities, palbociclib was withheld until resolution to < grade 2, and resumed at the next lower dose. Dose levels for dose reduction were 100, 75, and 50 mg; patients requiring reduction below 50 mg were discontinued.
Supportive care was allowed at the investigator's discretion, but strong inducers or inhibitors of CYP3A4 were prohibited.
Assessments:
Tumor assessments for response were conducted after every 2 cycles, using RECIST Version 1.0, by the RECIST core faculty of the Abramson Cancer Center blinded to patient identification and dose. Assessments were reduced to every 3 cycles for patients on treatment >18 months. intensity; equivocal = 2+ intensity or 3+ intensity in <30%; positive = 3+ staining in ≥30%, and separately assessed for nuclear and cytoplasmic compartments.
P16 was categorized as 0%, 1-24%, 25-75% and >75% per previous reports (18) , (19) . KI-67 staining was dichotomized at the 10% staining level (20) .
Amplification of CCND1 by FISH was defined by an 11q13:CEP ratio ≥2.2(17).
Statistical Analysis:
We defined tumor responses as "complete response' (CR), "partial response" (PR), stable disease (SD) and progressive disease (PD) per RECIST 1.0 criteria (13) . Because of the cytostatic mechanism of action of Author Manuscript Published OnlineFirst on December 11, 2014; DOI: 10.1158/1078-0432.CCR- required to move on to stage 2. Based on our observations in stage 1 of activity exclusively in HR+ patients, we set our primary goal in stage 2 to estimate the response rate specifically in HR+ disease, stratifying on this marker. A sample size of 30 response-evaluable patients with HR+ disease was required to confirm a clinical benefit rate between 5% (p0) and 25% (p1; α and β both set at 0.10).
We used Fisher's exact test to assess association of categorical variables. PFS was defined as the time from the date of the initial palbociclib treatment to the date of death or date of progression (whichever occurred first), and PFS curves were planned a priori for the study population overall, by receptor subset (HR+, Her2+ and ER-/Her2-), and by prior treatments. Patients who discontinued due to toxicity were censored at the date of study discontinuation. Log-rank tests were conducted to assess effects of receptor subsets and prior treatments on PFS.
Cox proportional hazards models were used to assess the effects of biomarkers on PFS. We estimated the effects of predictors on the probability of response by logistic regression. All analyses were conducted in STATA 13 (StataCorp; College Station, TX). 5% HR+/Her2+ and 11% HR-/Her2-(triple negative). This was also a heavily pretreated group, with a median of 2 prior chemotherapy regimens for metastatic disease, and up to 13 different regimens. Among those with HR+ tumors, the majority had also received prior hormone therapy, with 70% having at least 2 prior regimens.
RESULTS
Between
Efficacy: Among the first 15 breast cancer patients enrolled on the protocol, 2 had PR, meeting our prespecified criteria for continued enrollment. We completed full enrollment within the HR+ subset, but halted enrollment to the triple-negative cohort early because of observed rapid progression of enrolled patients and other treatment options available for this population.
Overall, CB was achieved in 7 of 37 patients, all in the 33 HR+ patients, for a clinical benefit rate (CBR) of 19% in the overall trial cohort and 21% in those who were HR+. Among HR+ patients, CB was seen exclusively in those patients who had already progressed through > 2 prior lines of hormonal therapy (7/24, or 29%). With regard to prior chemotherapy, CBR was greater among patients with fewer than 2 prior regimens for metastatic disease compared with those who were more heavily treated (44% vs. 11% p=0.045). Two patients in the HR+ subset also had tumors with Her2 overexpression. One patient experienced a PR; one patient had SD lasting 5 months. Neither Her2+ patient received concurrent Her2-directed therapy. 
Safety and Tolerability:
The incidence of adverse events by grade is shown in Table 3 . One patient chose to discontinue study therapy after 2 cycles because of grade 2 fatigue. This patient had undergone three prior chemotherapy regimens for metastatic disease, but did not experience grade 3 or 4 neutropenia, anemia or thrombocytopenia while on study therapy. No other patient was discontinued for toxicity and there were no treatment-related deaths.
Research. Myelosuppression, particularly neutropenia, led to dose interruptions and reductions ( Table 4) . 46% of all dose modifications were due to neutropenia, mostly grade 3. Among those with dose reductions, a significant fraction (19%) had more than one dose reduction for myelosuppression, with 7 patients being reduced to 50 or 75 mg daily. Of the 19 dose reductions, 14 (74%) occurred at the start of cycle 2, while only 3 occurred during cycle 1 (at the 2-week CBC), and just 1 occurred beyond cycle 2 (at cycle 5). These dose reductions did not appear to adversely affect response: among the 7 patients who experienced clinical benefit, only 2 remained at the 125 mg dose; 2 were reduced to 100 mg, 2 were reduced to 75 mg, and 1 was reduced to 50 mg, all with continued response.
Biomarker Assessment:
Representative sections for each of the biomarkers of interest, expression frequencies and associations with odds of response and hazards of progression None of the markers we evaluated were significantly associated with either clinical benefit or PFS, either at the a priori hypothesized cut-points or in exploratory analyses of continuous data both in the overall and HR+ groups (22) .
DISCUSSION
Palbociclib (PD0332991), an oral CDK4/6 inhibitor, demonstrates single-agent activity in this heavily pretreated population of patients with advanced BC. The CBR was 21% for patients with HR+ disease, but rose to 29% among those who had progressed through at least 2 prior lines of hormonal therapy, suggesting substantial activity in the setting of acquired endocrine resistance. These patients also had prolonged PFS (5 months) compared to those patients who had had only one line of prior endocrine therapy. Response duration in second line hormone therapy is typically 3-4 months, as evidenced by the 3.7 month PFS seen with both exemestane and fulvestrant in the phase III EFECT trial(23) and the 2.8 month PFS for the exemestane control arm in BOLERO-2(24). Thus the level of activity we saw in patients demonstrating prior endocrine resistance is encouraging, and will be further tested to some extent in the PALOMA-3 trial, combining palbociclib with fulvestrant in patients with endocrine-resistant BC. proliferation, but did not decrease total marrow cellularity, or alter apoptosis or viability of hematopoietic progenitor cells. These findings are corroborated by our clinical observation that short interruption followed by dose reduction was effective in restoring normal neutrophil counts. Thus, though the incidence of neutropenia is high, the relative paucity of fever and infection precludes this from being a major safety concern. It is not clear to what extent dose reductions altered response to therapy, however; response was seen at doses as low at 50 mg daily. However, the most common toxicity was diarrhea, which occurred in 43%, 17% and 6.4% of patients at grades 1, 2 and 3, respectively. Nausea, fatigue, and vomiting additionally occurred in at least 15% of patients. There was one episode of febrile neutropenia. Among this heavily pretreated cohort (median 7 lines of prior therapy), nineteen percent of patients experienced PR and 29.8% experienced >6 months SD. PR and 6 month SD rates increased to 25% and 
36%, respectively, among women with HR+ disease. The median PFS was 9.1 months with 18 patients still on study. The reasons for the increased singleagent response rate with this agent relative to LEE011 and palbociclib are not clear, but could be a result of a differing mechanism of action or a modulatory pharmacodynamic effect of continuous dosing. Continuous dosing has not been tested with palbociclib to date, precluding direct comparison of these agents.
Given the sample size constraints of this trial, we have interpreted our data with caution. We have reported only the pre-specified analyses for HR+ patients and comparison by prior therapy. We limited biomarker analyses to biologicallyhypothesized common cell cycle changes at prespecified cut-points and exploratory analysis of continuous variables, but because of the small samples, these findings in particular must be viewed as hypothesis-generating only, and warrant further study. Furthermore, other biomarkers may be important to predicting response to therapy. Recent data from the Engelman lab(31), for example, have suggested that PI3K alterations could sensitize tumors to the effects of cdk 4/6 inhibition and other alterations, such as Rb mutation or L0H could be important as well (32) . 
(60%)
Receptor Group: 
